Biodesix raises 2025 revenue guidance to $84M-$86M as primary care expansion accelerates

Sarepta’s stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints.

Seeking Alpha’s Disclaimer: The earnings call insights are compilations of earnings call transcripts and other…

The software company is boosting its outlook, and its CEO is cheering gains for retail…

Bitcoin has broken below an important technical level, which could signal further downside for the…

The U.S. coffee-shop chain is forming a joint venture with Boyu Capital, with Boyu holding…